Evox Therapeutics is harnessing and engineering the natural trafficking capabilities of extracellular vesicles to develop an entirely novel class of biotherapeutics. By combining groundbreaking exosome technology from well-renowned Oxford University and the Karolinska Institutet – the home of the Nobel Prize – we aim to revolutionise the treatment of a broad range of severe disease, with profound implications for human health. Based in Oxford, UK, Evox Therapeutics was founded in 2016 by Professor Matthew Wood of Oxford University, Assistant Professor Samir EL Andaloussi and Dr Per Lundin of the Karolinska Institutet, to capitalise on foundational intellectual property springing from the groundbreaking exosome research carried out in these two world-leading labs. Backed by Oxford Sciences Innovation and with a driven multidisciplinary team, Evox is building an exosome powerhouse focusing on the development of a modular platform for clinical translation of a broad range of exosome-based therapeutics. Evox Therapeutics has built a comprehensive intellectual property portfolio encompassing key aspects of EV-based nucleic acid and protein delivery technology. Coupled with targeting technology and proprietary manufacturing and purification methods, the company is set to develop transformational therapeutics across a wide range of disease areas, using an equally wide array of therapeutic modalities.
View Top Employees from Evox Therapeutics LtdWebsite | http://www.evoxtherapeutics.com/ |
Revenue | $12 million |
Funding | $156.9 million |
Employees | 139 (139 on RocketReach) |
Founded | 2016 |
Address | Oxford Science Park, Medwar Center, Oxford, England OX4 4HG, GB |
Phone | +44 1865 819140 |
Technologies |
JavaScript,
HTML,
Twitter
+16 more
(view full list)
|
Industry | Research Services, Business Services General, Biotechnology, Exosomes, Business Services, Science and Engineering, Natural Nanotechnology, Health Care, Biotherapeutics, Pharmaceutical, Research |
Web Rank | 5 Million |
Keywords | Evox Therapeutics, Evox, Bo Kara Evox Therapeutics |
SIC | SIC Code 873 Companies, SIC Code 87 Companies |
NAICS | NAICS Code 5417 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 541714 Companies, NAICS Code 54171 Companies |
Looking for a particular Evox Therapeutics Ltd employee's phone or email?
The Evox Therapeutics Ltd annual revenue was $12 million in 2024.
Matthew Ryan is the Senior Director Quality of Evox Therapeutics Ltd.
139 people are employed at Evox Therapeutics Ltd.
Evox Therapeutics Ltd is based in Oxford, England.
The NAICS codes for Evox Therapeutics Ltd are [5417, 54, 541, 541714, 54171].
The SIC codes for Evox Therapeutics Ltd are [873, 87].